"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...

CHICAGO (Reuters) - Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

Recent health updates see UnitedHealth shareholders challenging healthcare denial impacts. BRCA2 cancer gene mutation risks ...

Testing BRCA2 has long been a staple of hereditary cancer testing, as pathogenic variants in the gene are associated with cancers of the breast, ovary, prostate, and pancreas. 2-5 Despite the ...

Mr. Knowles is opening up about something else near and dear to his heart — his experience as a male breast cancer survivor ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...